Q BioMed (QBIO) 10-Q 14 Oct 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Aug. 31, 2020	Oct. 12, 2020
Document and Entity Information
Entity Registrant Name	Q BIOMED INC.
Document Type	10-Q
Document Period End Date	Aug. 31, 2020
Amendment Flag	false
Entity Central Index Key	0001596062
Current Fiscal Year End Date	--11-30
Entity Common Stock, Shares Outstanding		23,410,573
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	QBIO
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Aug. 31, 2020	Nov. 30, 2019
Current assets:
Cash	$ 1,326,359	$ 172,636
Accounts receivable	12,300	0
Prepaid expenses and other current assets	133,964	17,662
Total current assets	1,472,623	190,298
Intangible assets, net	412,500	450,000
Total Assets	1,885,123	640,298
Current liabilities:
Accounts payable	357,973	652,051
Accrued expenses	1,265,571	1,145,660
Accrued expenses - related party	4,000	7,500
Accrued interest payable	40,876	189,801
Convertible note payable, net	0	3,243,292
Total current liabilities	1,668,420	5,238,304
Long-term liabilities:
Total long term liabilities	90,096	447,335
Total Liabilities	1,758,516	5,685,639
Commitments and Contingencies (Note 6)
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value; 100,000,000 shares authorized as of August 31, 2020 and November 30, 2019
Common stock, $0.001 par value; 250,000,000 shares authorized; 22,774,232 and 19,709,068 shares issued and outstanding as of August 31, 2020 and November 30, 2019, respectively	22,774	19,709
Additional paid-in capital	45,345,017	37,328,827
Accumulated deficit	(52,456,003)	(42,393,877)
Total Stockholders' Equity (Deficit)	126,607	(5,045,341)
Total Liabilities and Stockholders' Equity (Deficit)	1,885,123	$ 640,298
Convertible Series A Preferred Stock
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value; 100,000,000 shares authorized as of August 31, 2020 and November 30, 2019	2,189,846
Convertible Series B Preferred Stock
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value; 100,000,000 shares authorized as of August 31, 2020 and November 30, 2019	$ 5,024,973

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Aug. 31, 2020	Nov. 30, 2019
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	22,774,232	19,709,068
Common stock, shares outstanding	22,650,685	19,709,068
Convertible Series A Preferred Stock
Preferred stock, shares authorized	500,000	500,000
Preferred stock, issued	227,998	0
Preferred stock, outstanding	227,998	0
Convertible Series B Preferred Stock
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	503,134	0
Preferred stock, outstanding	503,134	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2020	Aug. 31, 2019	Aug. 31, 2020	Aug. 31, 2019
Condensed Consolidated Statements of Operations
Net Sales	$ 15,000	$ 0	$ 30,000	$ 0
Cost of sales	158,516	0	193,211	0
Gross loss	(143,516)	0	(163,211)	0
Operating expenses:
General and administrative expenses	1,491,613	968,383	8,659,819	3,406,853
Research and development expenses	613,707	786,600	896,908	2,672,715
Total operating expenses	2,105,320	1,754,983	9,556,727	6,079,568
Loss from operations	(2,248,836)	(1,754,983)	(9,719,938)	(6,079,568)
Other (income) expenses:
Interest expense	9,025	476,627	291,626	1,137,271
Change in fair value of embedded derivatives	0	118,000	19,163	396,000
Loss on induced conversion of debt	0	197,078	0	197,078
Loss on debt extinguishment	0	0	31,399	0
Total other expenses	9,025	791,705	342,188	1,730,349
Net loss	(2,257,861)	(2,546,688)	(10,062,126)	(7,809,917)
Accumulated dividend on convertible preferred stock	(146,227)	0	(230,699)	0
Deemed dividend on convertible preferred stock due to beneficial conversion feature	0	0	(482,945)	0
Net loss attributable to common stockholders	$ (2,404,088)	$ (2,546,688)	$ (10,775,770)	$ (7,809,917)
Net loss per share - basic and diluted	$ (0.11)	$ (0.17)	$ (0.50)	$ (0.54)
Weighted average shares outstanding, basic and diluted	22,433,141	14,756,302	21,731,159	14,580,630

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Shareholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid in CapitalSeries A convertible preferred stock	Additional Paid in CapitalSeries B convertible preferred stock	Additional Paid in Capital	Accumulated Deficit	Series A convertible preferred stock	Series B convertible preferred stock	Total
Beginning balance, Shares at Nov. 30, 2018	14,290,236
Beginning balance, Amount at Nov. 30, 2018	$ 14,290			$ 31,994,129	$ (32,114,147)			$ (105,728)
Share based compensation for services, Amount	$ 527			1,349,081				1,349,608
Share based compensation for services, Shares	526,541
Issuance of common stock to partially convert notes payable	$ 147			293,579				293,726
Issuance of common stock to partially convert notes payable (in shares)	146,863
Issuance of common stock as inducement to partially convert notes payable	$ 188			196,890				197,078
Issuance of common stock as inducement to partially convert notes payable (in shares)	187,693
Issuance of common stock to defer monthly contingent payment of convertible note	30			32,408				32,438
Issuance of common stock to defer monthly contingent payment of convertible note (in shares)	$ 30,894
Net loss					(7,809,917)			(7,809,917)
Ending balance, Shares at Aug. 31, 2019	15,182,227
Ending balance, Amount at Aug. 31, 2019	$ 15,182			33,866,087	(39,924,064)			(6,042,795)
Beginning balance, Shares at May. 31, 2019	14,677,136
Beginning balance, Amount at May. 31, 2019	$ 14,676			33,002,224	(37,377,376)			(4,360,476)
Share based compensation for services, Amount	$ 141			340,986				341,127
Share based compensation for services, Shares	139,641
Issuance of common stock to partially convert notes payable	$ 147			293,579				293,726
Issuance of common stock to partially convert notes payable (in shares)	146,863
Issuance of common stock as inducement to partially convert notes payable	$ 188			196,890				197,078
Issuance of common stock as inducement to partially convert notes payable (in shares)	187,693
Issuance of common stock to defer monthly contingent payment of convertible note	30			32,408				32,438
Issuance of common stock to defer monthly contingent payment of convertible note (in shares)	$ 30,894
Net loss					(2,546,688)			(2,546,688)
Ending balance, Shares at Aug. 31, 2019	15,182,227
Ending balance, Amount at Aug. 31, 2019	$ 15,182			33,866,087	(39,924,064)			(6,042,795)
Beginning balance, Shares at Nov. 30, 2019	19,709,068
Beginning balance, Amount at Nov. 30, 2019	$ 19,709			37,328,827	(42,393,877)			(5,045,341)
Issuance of Series A and Series B preferred stock for cash, Amount						$ 975,000	$ 2,975,000	3,950,000
Number of shares issued for cash						100,000	300,000
Issuance of Series A and Series B preferred stock to convert notes payable, Amount						$ 1,279,980	$ 2,031,340	3,311,320
Issuance of Series A and Series B preferred stock to convert notes payable, Shares						127,998	203,134
Offering cost related issuance of Series A and Series B preferred stock				277,200		$ (138,600)	$ (138,600)
Cashless warrants exercise, Amount	$ 21			(21)
Cashless warrants exercise, Shares	20,860
Beneficial conversion feature of convertible preferred stock		$ 252,786				(252,786)
Beneficial conversion feature of Series B convertible preferred stock			$ 230,159				(230,159)
Deemed dividends related to immediate accretion of beneficial conversion feature of convertible preferred stock		$ (252,786)	$ (230,159)			252,786	230,159
Accumulated dividend on convertible preferred stock				(230,699)		$ 73,466	$ 157,233
Share based compensation for services, Amount	$ 233			4,982,213				4,982,446
Share based compensation for services, Shares	233,106
Share based compensation related to warrants modification, Amount				255,008				255,008
Issuance of common stock to partially convert notes payable	$ 2,811			2,732,489				2,735,300
Issuance of common stock to partially convert notes payable (in shares)	2,811,198
Net loss					(10,062,126)			(10,062,126)
Ending balance, Shares at Aug. 31, 2020	22,774,232					227,998	503,134
Ending balance, Amount at Aug. 31, 2020	$ 22,774			45,345,017	(52,456,003)	$ 2,189,846	$ 5,024,973	126,607
Beginning balance, Shares at May. 31, 2020	22,650,685					227,998	503,134
Beginning balance, Amount at May. 31, 2020	$ 22,650			45,219,938	(50,198,142)	$ 2,144,246	$ 4,924,346	2,113,038
Accumulated dividend on convertible preferred stock				(146,227)		$ 45,600	$ 100,627
Share based compensation for services, Amount	$ 124			271,306				271,430
Share based compensation for services, Shares	123,547
Net loss					(2,257,861)			(2,257,861)
Ending balance, Shares at Aug. 31, 2020	22,774,232					227,998	503,134
Ending balance, Amount at Aug. 31, 2020	$ 22,774			$ 45,345,017	$ (52,456,003)	$ 2,189,846	$ 5,024,973	$ 126,607

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Cash Flows - USD ($)	9 Months Ended
	Aug. 31, 2020	Aug. 31, 2019
Cash flows from operating activities:
Net loss	$ 10,062,126	$ 7,809,917
Adjustments to reconcile net loss to net cash used in operating activities
Share based compensation for services	4,982,446	1,349,608
Share based compensation related to warrants modification	255,008	0
Change in fair value of embedded conversion option	19,163	396,000
Accretion of debt discount	136,705	907,437
Amortization expense	37,500	37,500
Loss on debt extinguishment	31,399	0
Loss on induced conversion of debt	0	197,078
Non-cash interest expense	0	32,438
Changes in operating assets and liabilities:
Accounts receivable	(12,300)	0
Prepaid expenses	(116,302)	(16,046)
Accounts payable and accrued expenses	(187,667)	1,646,699
Accrued expenses - related party	0	17,500
Accrued interest payable	154,897	165,713
Net cash used in operating activities	(4,761,277)	(3,075,990)
Cash flows from financing activities:
Proceeds from issuance of Series A and Series B convertible preferred stock, net of issuance costs	3,950,000	0
Proceeds received from issuance of convertible note	1,965,000	500,000
Proceeds from investor advances	0	193,250
Net cash provided by financing activities	5,915,000	693,250
Net increase (decrease) in cash	1,153,723	(2,382,740)
Cash at beginning of period	172,636	2,684,413
Cash at end of the period	1,326,359	301,673
Supplemental disclosures:
Cash paid for interest	0	31,524
Cash paid for income taxes	0	0
Supplemental disclosures for noncash investing and financing activities:
Issuance of common stock to convert notes payable and accrued interest	2,735,300	293,726
Accrued debt issuance costs	0	15,000
Issuance of Series A and Series B preferred stock in exchange for outstanding convertible notes payable and accrued interest	3,311,320	0
Accumulated dividend on convertible preferred stock	230,699	0
Shares payable related to debt modification	$ 10,000	$ 0

Organization of the Company and

Organization of the Company and Description of the Business	9 Months Ended
	Aug. 31, 2020
Organization of the Company and Description of the Business
Organization of the Company and Description of the Business	Note 1 - Organization of the Company and Description of the Business Q BioMed Inc. (“Q BioMed”) and its wholly owned subsidiaries Q BioMed Cayman SEZC and QBMG Q BioMed Germany UG (collectively, “the Company”), is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or spinoff new public companies. The accompanying condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

Financial Condition, Going Conc

Financial Condition, Going Concern and Management Plans	9 Months Ended
	Aug. 31, 2020
Financial Condition, Going Concern and Management Plans
Financial Condition, Going Concern and Management Plans	Note 2 – Financial Condition, Going Concern and Management Plans The Company currently operates in one business segment focusing on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business. The accompanying condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has and is expected to incur net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters, amongst others, raise doubt about the Company’s ability to continue as a going concern. The Company does not generate material revenue from operations since inception and has limited assets upon which to commence its business operations. Management anticipates that the Company will have to raise additional funds and/or generate significant revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management will be forced to scale back the Company’s operations or cease its operations. Management has determined that there is substantial doubt about the Company's ability to continue as a going concern within one year after the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. The impact of the worldwide spread of a novel strain of coronavirus (“COVID-19”) has been unprecedented and unpredictable, but based on the Company’s current assessment, the Company does not expect any material impact on its long-term strategic plans, operations and its liquidity due to the worldwide spread of COVID-19. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world and its assessment of the impact of COVID-19 may change.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Aug. 31, 2020
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 - Summary of Significant Accounting Policies Basis of Presentation The accompanying interim period unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. These condensed consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended November 30, 2019. Certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. These unaudited consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for a full year. The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended November 30, 2019 included in the Company’s Form 10-K. Revenue Recognition The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. Previous practices were broadly consistent with this approach, and the company determined the amount of revenue based on the amount customer paid or promised to pay. The Company satisfies its performance obligation to deliver products when the customer has received the products, which is when title to the goods has transferred and the customer has control of the products. Payments from customers are generally received within 90 days of when the product is delivered. Because the Company’s agreements have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations. Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash held in banks and accounts receivable. Cash is maintained in accounts with financial institutions, which, at times may exceed the federal depository insurance coverage of $250,000. At August 31, 2020, the Company has not experienced losses on these cash accounts. The Company sells its product through a global marketer, wholesale distributors and specialty contracted pharmacies on 90-day or better payment terms. The Company continuously monitors the creditworthiness of its customers and adheres to internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on historical payment patterns, aging of receivable balances and general economic conditions. The Company has not experienced any credit losses to-date. Recent Accounting Standards In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for the Company on December 1, 2022, Early adoption is permitted, but no earlier than December 1, 2021. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures. Recently Adopted Standards On February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the use of, a specified asset for the lease term. The Company adopted ASC 842 on December 1, 2019, using the optional transition method to apply the new guidance as of December 1, 2019, rather than as of the earliest period presented, and elected the package of practical expedients described above. The adoption of this standard on December 1, 2019 did not impact the Company’s condensed consolidated financial statements as the Company is not subject to any lease agreements on December 1, 2019. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The adoption of this standard on December 1, 2019, did not impact the Company’s condensed consolidated financial statements.

Loss per share

Loss per share	9 Months Ended
	Aug. 31, 2020
Loss per share
Loss per share	Note 4 – Loss per share Basic net loss per share was calculated by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. Diluted net loss per share was calculated by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive. Potentially dilutive securities August 31, 2020 November 30, 2019 Series A convertible preferred stock 2,280,000 — Series B convertible preferred stock 3,787,000 — Warrants 9,801,000 7,180,000 Stock Options 2,150,000 1,200,000 Convertible Notes 56,000 5,732,000 Potentially dilutive securities 18,074,000 14,112,000

Convertible Notes

Convertible Notes	9 Months Ended
	Aug. 31, 2020
Convertible Notes.
Convertible Notes	Note 5 - Convertible Notes August 31, 2020 November 30, 2019 Convertible Notes Payable, current: Principal value of 2018 Debenture $ — $ 2,730,000 Fair value of bifurcated contingent put option — 74,000 Debt discount — (61,000) Carrying value of 2018 Debenture — 2,743,000 Principal value of 2019 August Debenture — 550,000 Debt discount — (50,000) Carrying value of 2019 August Debenture — 500,000 Total carrying value of convertible notes payable, current $ — $ 3,243,000 Convertible Notes Payable, long-term: Principal value of 2019 October Debenture $ — $ 500,000 Fair value of bifurcated contingent put option — 29,000 Debt discount — (82,000) Carrying value of 2019 October Debenture — 447,000 Principal value of 2019 August Debenture 100,000 — Debt discount (10,000) — Carrying value of 2019 August Debenture 90,000 — Total carrying value of convertible notes, long-term $ 90,000 $ 447,000 During the nine months ended August 31, 2020, the Company raised approximately $2.0 million from the issuance of various debentures (the “Debentures”). The Debentures have a maturity date of June 6, 2021. The Debentures bear interest at the rate of 5.5% per annum, and on issuance, the Company paid to the holder a commitment fee equal to 2.5% of the amount of the Debentures. The Debentures may be converted at any time on or prior to maturity at the lower of $3.00 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the Debenture, the conversion price may never be less than $2.00. Any time after the six-month anniversary of the issuance of the Debentures that the daily VWAP is less than $2.00 for a period of twenty consecutive trading days (the “Triggering Date”) and only for so long as such conditions exist after a Triggering Date, the Company shall make monthly payments beginning on the last calendar day of the month when the Triggering Date occurred. Each monthly payment shall be in an amount equal to the sum of (i) the principal amount outstanding as of the Triggering Date divided by the number of such monthly payments until maturity, (ii) a redemption premium of 20% in respect of such principal amount and (iii) accrued and unpaid interest hereunder as of each payment date. The Company may, no more than twice, obtain a thirty-day deferral of a monthly payment due as a result of a Triggering Date through the payment of a deferral fee in the amount equal to 10% of the total amount of such monthly payment. Each deferral payment may be paid at the option of the Company in cash or by the issuance of such number of shares as is equal to the applicable deferral payment divided by a price per share equal to 93% of the average of the four lowest daily VWAPs during the 10 consecutive Trading Days immediately preceding the due date in respect of such monthly payment being deferred, provided that such shares issued will be immediately freely tradable shares in the hands of the holder. Upon issuance of the Debentures, the Company recognized a debt discount of approximately $0.3 million, resulting from the recognition of issuance costs of $35,000 and a bifurcated embedded derivative of $0.3 million.The monthly payment provision within the Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs: January 15, 2020 December 6, 2019 Strike price $ 3.00 $ 3.00 Terms (years) 1.4 1.5 Volatility 97 % 98 % Risk-free rate 1.7 % 1.6 % Dividend yield 0 % 0 % The following table summarizes key inputs for embedded convers features on the date of conversions: Conversion Date Strike price $1.00 - $3.00 Terms (years) 0.8 Volatility 126 % Risk-free rate 0.2 % Dividend yield 0 % As of August 31, 2020, there are no notes outstanding with embedded conversion features. Debt Conversion The following table summarizes debt conversion during the nine months ended August 31, 2020: Principal value of 2018 Debenture $ 2,730,000 Remaining debt discount (28,000) Accrued interest 223,000 Fair value of bifurcated contingent put option 126,000 Sub-total 3,051,000 Principal value of 2019 Debenture 1,950,000 Remaining debt discount (220,000) Accrued interest 58,000 Fair value of bifurcated contingent put option 157,000 Sub-total 1,945,000 Principal value of 2020 Debenture 1,000,000 Remaining debt discount (140,000) Accrued interest 22,000 Fair value of bifurcated contingent put option 137,000 Sub-total 1,019,000 Total debt conversion amount 6,015,000 Fair value of Series A convertible preferred stock issued (127,998 shares) 1,280,000 Fair value of Series B convertible preferred stock issued (2,031,340 shares) 2,031,000 Fair value of common stock issued (2,811,198 shares) 2,735,000 Loss on debt extinguishment during the nine months ended August 31, 2020 $ (31,000) Debt Modification On August 25, 2020, the Company entered into an extension agreement (the “Agreement”) with the holder of August 2019 debenture (the “Holder”) to extend the maturity date from August 29, 2020 to September 30, 2021. As a consideration, the Company agreed to issue the Holder $10,000 worth of common stock on or before September 30, 2020 based on the closing price on August 25, 2020. The Agreement was recognized as a debt modification. The Company recognized an additional $10,000 debt discount on the amendment date, which will be amortized to interest expense over the remaining term of the debt. Interest expense Interest expense, included in the accompanying Condensed Consolidated Statements of Operations, is comprised of the following for each period presented: For the Three Months ended For the Nine Months ended August 31, 2020 August 31, 2019 August 31, 2020 August 31, 2019 Interest expense based on the coupon interest rate of the outstanding debt $ 6,000 $ 55,000 $ 156,000 $ 166,000 Accretion of debt discount 3,000 390,000 136,000 907,000 Costs incurred to defer monthly contingent payments of convertible notes — 32,000 — 64,000 Total interest expense $ 9,000 $ 477,000 $ 292,000 $ 1,137,000

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Aug. 31, 2020
Commitments and Contingencies
Commitments and Contingencies	Note 6 - Commitments and Contingencies Legal Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Aug. 31, 2020
Related Party Transactions
Related Party Transactions	Note 7 - Related Party Transactions The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations as follows: For the Three Months ended For the Nine Months ended August 31, 2020 August 31, 2019 August 31, 2020 August 31, 2019 Consulting and legal expenses $ 105,000 $ 78,000 $ 315,000 $ 270,000

Stockholders' Equity Deficit

Stockholders' Equity Deficit	9 Months Ended
	Aug. 31, 2020
Stockholders' Equity Deficit
Stockholders' Equity Deficit	Note 8 - Stockholders’ Equity Deficit Common Shares Issuance of shares for services During the nine months ended August 31, 2020, the Company issued an aggregate of 0.2 million shares of the Company common stock to various vendors for advisory services, valued at approximately $0.5 million based on the estimated fair market value of the stock on the date of grant and was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. Preferred Shares Amendments to Articles of Incorporation or Bylaws On April 3, 2020, the Company’s Board of Directors authorized the creation of up to 500,000 shares of Series A Convertible Preferred Stock (the “Series A Preferred Shares”) and up to 1,000,000 shares of Series B Convertible Preferred Stock (the “Series B Preferred Shares”). On April 6, 2020, the Company filed a Certificate of Designations with the Secretary of Nevada creating such Series A and Series B Preferred Shares (collectively, the “Preferred Shares”). The original issue price and the liquidation value per share, as of August 31, 2020, of each class of preferred stock is as follows: Original Issue Price Liquidation Value Per Share Per Share Series A Preferred Share $ 10.00 $ 10.32 Series B Preferred Share $ 10.00 $ 10.31 The following is a summary of the rights of the holders of the Preferred Shares: Voting . Except to the extent required by law, the holders of the Preferred Shares do not have the right to vote on the matters that the holders of the common stock have the right to vote upon. The holders of the Preferred Shares may vote upon matters affecting the Preferred Shares, provided that if the vote concerns all Preferred Shares, the holders of the Series A Preferred Shares shall vote together with the holders of the Series B Preferred Shares. Liquidation . The holders of the Preferred Shares have a liquidation preference over the holders of the common stock. Such preference consists of the right to receive upon the Company’s voluntary or involuntary liquidation, dissolution or winding up the liquidation value of each Series A and Series B Preferred Share prior to the payment of any amounts to the holders of the common stock. The liquidation value of each Series A and Series B Preferred Share shall be equal to $10 plus any accrued but unpaid dividends thereon. Dividends . Every three months, the Company is required to pay each holder of Preferred Shares a dividend equal to 2% of the liquidation value of such shares (which is equal to 8% on annual basis). Such dividends shall be paid in shares of the Company’s common stock in an amount equal to the dollar amount of such payment divided by the VWAP of the Company’s common stock on the date that such dividend payment is due, provided that the Company may not issue such shares of common stock if such share issuance would cause the holder to beneficially own more than 9.99% of the Company’s common stock. Conversion of Series A Preferred Shares . Each Series A Preferred Share may be converted into shares of the Company’s common stock in an amount that is equal to the liquidation value divided by $1.00. The Company may force the conversion of the Series A Preferred Shares if each of the following conditions (the “Forced Equity Conditions”) has been met: (i) on each trading day during the period beginning ten trading days prior to the forced conversion (the "Equity Conditions Measuring Period"), the VWAP of the Company’s common stock is in excess of $5.00, (ii) on each trading day during Equity Conditions Measuring Period, the dollar volume of the Company’s common stock traded is in excess of $750,000, (iii) on each day during the Equity Conditions Measuring Period, the shares of the Company’s common stock underlying the Series A Preferred Shares to be converted shall either (x) be registered for resale on an effective registration statement or (y) eligible for resale without restriction and without the need for registration under any applicable federal or state securities laws, (iv) on each day during the Equity Conditions Measuring Period, the Company’s common stock is designated for quotation on the Company’s principal market and shall not have been suspended from trading on such exchange or market nor shall delisting or suspension by such exchange or market been threatened or pending either (A) in writing by such exchange or market or (B) by falling below the then effective minimum listing maintenance requirements of such exchange or market; and (v) during the Equity Conditions Measuring Period, there shall not have occurred either (A) an Event of Default or (B) an event that with the passage of time or giving of notice would constitute an Event of Default. Conversion of Series B Preferred Shares . Each Series B Preferred Share may be converted into shares of the Company’s common stock in an amount that is equal to the liquidation value divided by the applicable conversion rate. The conversion rate shall be the lower of: (a) $2.70 or (b) 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that the conversion price may not be less than $1.00; further provided that if the VWAP of the Company’s common stock for any 40 consecutive trading days is less than $1.00 for 30 of those days, then such floor conversion price shall be reduced from $1.00 to $0.35. The Company may not issue shares of common stock upon pursuant to the conversions discussed above if such conversion would cause a holder to beneficially own more than 9.99% of our then outstanding common stock. Financing Agreements On April 6, 2020, the Company entered into a securities purchase agreement (the “SPA”) with accredited investors (the “Investors”). Pursuant to the SPA, the Company issued the following securities: · 127,998 shares of Series A Convertible Preferred Stock (the “Series A”) in exchange for convertible debentures with principal and interest of approximately $1.3 million; · 100,000 Series A Preferred Shares for cash of $1.0 million, · 203,134 shares of Series B Convertible Preferred Stock (‘the “Series B”) in exchange for convertible debentures with principal and interest of approximately $2.0 million; · 300,000 Series B Preferred Shares for cash of $3.0 million The fair value of the Company’s common stock on the issuance date is higher than the effective conversion price of both the Series A Preferred Shares and the Series B Preferred Shares (collectively, the “Preferred Shares”), therefore the Company recorded a beneficial conversion feature (“BCF”) of approximately $0.5 million on the Preferred Shares. The discount to the aggregate stated value of the Preferred Shares, resulting from recognition of the BCF was immediately accreted as a reduction of additional paid-in capital and an increase in the carrying value of the Preferred Shares. The accretion is presented in the Consolidated Statement of Operations as a deemed dividend, increasing net loss to arrive at net loss attributable to common stockholders. The Company had accumulated dividends payable on the Preferred Shares of approximately $0.2 million as of August 31, 2020.

Warrants and Options

Warrants and Options	9 Months Ended
	Aug. 31, 2020
Warrants and Options
Warrants and Options	Note 9 – Warrants and Options Summary of warrants The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants issued as part of the units sold in the private placements, at May 31, 2020 and the changes during the period then ended: Weighted Average Weighted Remaining Average Contractual Warrants Exercise Price Life (years) Intrinsic Value Outstanding at December 1, 2019 7,180,000 $ 2.22 3.2 $ 2,463,000 Issued 3,065,000 2.13 4.3 — Cashless exercise (30,000) 0.86 — — Forfeited/expired (414,000) 3.95 — — Outstanding at August 31, 2020 9,801,000 $ 2.11 3.1 $ 1,668,000 Exercisable at August 31, 2020 9,788,000 $ 2.11 3.1 $ 1,668,000 During the nine months ended August 31, 2020, the Company issued 1,500,000 warrants to the Company’s two officers in exchange for services rendered. The warrants are exercisable into shares of the Company’s common stock in six months from their issuance until five years from the date of issuance at an exercise price of $2.12 per share. During the nine months ended August 31, 2020, the Company issued 901,000 warrants to certain consultants and service providers in exchange for services rendered. The warrants are exercisable into shares of the Company’s common stock between 3-5 years from the date of issuance at an exercise price between $2.00 to $2.12 per share. During the nine months ended August 31, 2020, the Company issued 250,000 warrants to certain consultants for legal services provided regarding issuance of Preferred Shares and preparation of registration statement. The warrants are exercisable into shares of the Company’s common stock in six months from their issuance until five years from the date of issuance at an exercise price of $2.12 per share. The Company recorded approximately $0.1 million as a direct offering cost in Stockholders’ equity. The following assumptions were used to estimate the fair value of warrants granted during the nine months ended August 31, 2020: For the Nine Months ended August 31, 2020 Strike price $ 2.12 Term (years) Volatility 120 % Risk-free rate 1.3 % Dividend yield 0.0 % Modification of Warrants On February 12, 2020, the Company modified an aggregate of 245,625 warrants that were originally granted to certain investors and consultants. The exercise price of the warrants was reduced to $2.33 per share and the term of the warrants were extended for 2 years from the original expiration date. The Company received $20,000 cash from one of the investors as consideration for this modification. On May 1, 2020, the Company modified an aggregated of 168,000 warrants that were originally granted to certain consultants. The exercise price of the warrants was reduced to $2.00 per share and the term of the warrants were extended for 2-3 years from the original expiration date. The Company immediately recognized approximately $0.2 million of incremental stock-based compensation for the modifications during the nine months ended August 31, 2020 based on the following weighted average assumptions: After Modification Before Modification Strike price $ 2.20 $ 4.20 Term (years) 3.7 1.5 Volatility 124 % 164 % Risk-free rate 0.9 % 1.1 % Dividend yield 0.0 % 0.0 % Options Issued for Services The following represents a summary of all outstanding options to purchase the Company’s common stock at August 31, 2020 and the changes during the period then ended: Weighted Average Weighted Remaining Average Contractual Options Exercise Price Life (years) Intrinsic Value Outstanding at December 1, 2019 1,200,000 $ 1.35 3.4 $ 721,000 Issued 950,000 1.46 4.9 — Outstanding at August 31, 2020 2,150,000 $ 1.40 3.6 $ 161,000 Exercisable at August 31, 2020 1,290,000 $ 1.36 2.7 $ 161,000 The following assumptions were used to compute the fair value of options granted during the nine months ended August 31, 2020: For the Nine Months ended August 31, 2020 Strike price $ 1.46 Term (years) 5.00 Volatility 115 % Risk-free rate 0.5 % Dividend yield 0.0 % Stock-based Compensation The Company recognized general and administrative expenses of approximately $5 million and $0.5 million as a result of the shares, outstanding warrants and options issued to consultants and employees during the nine months ended August 31, 2020 and 2019, respectively. As of August 31, 2020, the estimated unrecognized stock-based compensation associate with these agreements is approximately $0.9 million and will be fully recognized over the next 12 months.

Subsequent Events

Subsequent Events	9 Months Ended
	Aug. 31, 2020
Subsequent Events
Subsequent Events	Note 10 – Subsequent Events On September 15, 2020, the Company issued 416,667 shares of common stock to Mannin to settle outstanding payables of $0.75 million, which was net of $61,000 receivables. The fair value the common shares was approximately $0.55 million on September 15, 2020.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Aug. 31, 2020
Summary of Significant Accounting Policies
Revenue Recognition	Revenue Recognition The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. Previous practices were broadly consistent with this approach, and the company determined the amount of revenue based on the amount customer paid or promised to pay. The Company satisfies its performance obligation to deliver products when the customer has received the products, which is when title to the goods has transferred and the customer has control of the products. Payments from customers are generally received within 90 days of when the product is delivered. Because the Company’s agreements have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash held in banks and accounts receivable. Cash is maintained in accounts with financial institutions, which, at times may exceed the federal depository insurance coverage of $250,000. At August 31, 2020, the Company has not experienced losses on these cash accounts. The Company sells its product through a global marketer, wholesale distributors and specialty contracted pharmacies on 90-day or better payment terms. The Company continuously monitors the creditworthiness of its customers and adheres to internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on historical payment patterns, aging of receivable balances and general economic conditions. The Company has not experienced any credit losses to-date.
Recent Accounting Standards and Recently Adopted Standards	Recent Accounting Standards In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. The ASU is effective for the Company on December 1, 2022, Early adoption is permitted, but no earlier than December 1, 2021. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures. Recently Adopted Standards On February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the use of, a specified asset for the lease term. The Company adopted ASC 842 on December 1, 2019, using the optional transition method to apply the new guidance as of December 1, 2019, rather than as of the earliest period presented, and elected the package of practical expedients described above. The adoption of this standard on December 1, 2019 did not impact the Company’s condensed consolidated financial statements as the Company is not subject to any lease agreements on December 1, 2019. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The adoption of this standard on December 1, 2019, did not impact the Company’s condensed consolidated financial statements.

Loss per share (Tables)

Loss per share (Tables)	9 Months Ended
	Aug. 31, 2020
Loss per share
Schedule of potentially dilutive securities not considered in the computation of diluted net loss per share	The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive. Potentially dilutive securities August 31, 2020 November 30, 2019 Series A convertible preferred stock 2,280,000 — Series B convertible preferred stock 3,787,000 — Warrants 9,801,000 7,180,000 Stock Options 2,150,000 1,200,000 Convertible Notes 56,000 5,732,000 Potentially dilutive securities 18,074,000 14,112,000

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
	Aug. 31, 2020
Convertible Notes.
Schedule of convertible notes payable, current and long-term	August 31, 2020 November 30, 2019 Convertible Notes Payable, current: Principal value of 2018 Debenture $ — $ 2,730,000 Fair value of bifurcated contingent put option — 74,000 Debt discount — (61,000) Carrying value of 2018 Debenture — 2,743,000 Principal value of 2019 August Debenture — 550,000 Debt discount — (50,000) Carrying value of 2019 August Debenture — 500,000 Total carrying value of convertible notes payable, current $ — $ 3,243,000 Convertible Notes Payable, long-term: Principal value of 2019 October Debenture $ — $ 500,000 Fair value of bifurcated contingent put option — 29,000 Debt discount — (82,000) Carrying value of 2019 October Debenture — 447,000 Principal value of 2019 August Debenture 100,000 — Debt discount (10,000) — Carrying value of 2019 August Debenture 90,000 — Total carrying value of convertible notes, long-term $ 90,000 $ 447,000
Schedule of discounted maximum redemption premium	January 15, 2020 December 6, 2019 Strike price $ 3.00 $ 3.00 Terms (years) 1.4 1.5 Volatility 97 % 98 % Risk-free rate 1.7 % 1.6 % Dividend yield 0 % 0 % The following table summarizes key inputs for embedded convers features on the date of conversions: Conversion Date Strike price $1.00 - $3.00 Terms (years) 0.8 Volatility 126 % Risk-free rate 0.2 % Dividend yield 0 %
Schedule of debt conversion	The following table summarizes debt conversion during the nine months ended August 31, 2020: Principal value of 2018 Debenture $ 2,730,000 Remaining debt discount (28,000) Accrued interest 223,000 Fair value of bifurcated contingent put option 126,000 Sub-total 3,051,000 Principal value of 2019 Debenture 1,950,000 Remaining debt discount (220,000) Accrued interest 58,000 Fair value of bifurcated contingent put option 157,000 Sub-total 1,945,000 Principal value of 2020 Debenture 1,000,000 Remaining debt discount (140,000) Accrued interest 22,000 Fair value of bifurcated contingent put option 137,000 Sub-total 1,019,000 Total debt conversion amount 6,015,000 Fair value of Series A convertible preferred stock issued (127,998 shares) 1,280,000 Fair value of Series B convertible preferred stock issued (2,031,340 shares) 2,031,000 Fair value of common stock issued (2,811,198 shares) 2,735,000 Loss on debt extinguishment during the nine months ended August 31, 2020 $ (31,000)
Schedule of interest expense	For the Three Months ended For the Nine Months ended August 31, 2020 August 31, 2019 August 31, 2020 August 31, 2019 Interest expense based on the coupon interest rate of the outstanding debt $ 6,000 $ 55,000 $ 156,000 $ 166,000 Accretion of debt discount 3,000 390,000 136,000 907,000 Costs incurred to defer monthly contingent payments of convertible notes — 32,000 — 64,000 Total interest expense $ 9,000 $ 477,000 $ 292,000 $ 1,137,000

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Aug. 31, 2020
Related Party Transactions
Schedule of general and administrative expenses	For the Three Months ended For the Nine Months ended August 31, 2020 August 31, 2019 August 31, 2020 August 31, 2019 Consulting and legal expenses $ 105,000 $ 78,000 $ 315,000 $ 270,000

Stockholders' Equity Deficit (T

Stockholders' Equity Deficit (Tables)	9 Months Ended
	Aug. 31, 2020
Stockholders' Equity Deficit
Schedule original issue price and the liquidation value per share for each class of preferred stock	The original issue price and the liquidation value per share, as of August 31, 2020, of each class of preferred stock is as follows: Original Issue Price Liquidation Value Per Share Per Share Series A Preferred Share $ 10.00 $ 10.32 Series B Preferred Share $ 10.00 $ 10.31

Warrants and Options (Tables)

Warrants and Options (Tables)	9 Months Ended
	Aug. 31, 2020
Schedule of fair value outstanding warrants and options issued to non-employees for services	For the Nine Months ended August 31, 2020 Strike price $ 2.12 Term (years) Volatility 120 % Risk-free rate 1.3 % Dividend yield 0.0 % After Modification Before Modification Strike price $ 2.20 $ 4.20 Term (years) 3.7 1.5 Volatility 124 % 164 % Risk-free rate 0.9 % 1.1 % Dividend yield 0.0 % 0.0 %
Warrants
Summary of warrants	Weighted Average Weighted Remaining Average Contractual Warrants Exercise Price Life (years) Intrinsic Value Outstanding at December 1, 2019 7,180,000 $ 2.22 3.2 $ 2,463,000 Issued 3,065,000 2.13 4.3 — Cashless exercise (30,000) 0.86 — — Forfeited/expired (414,000) 3.95 — — Outstanding at August 31, 2020 9,801,000 $ 2.11 3.1 $ 1,668,000 Exercisable at August 31, 2020 9,788,000 $ 2.11 3.1 $ 1,668,000
Stock Options
Schedule of fair value outstanding warrants and options issued to non-employees for services	For the Nine Months ended August 31, 2020 Strike price $ 1.46 Term (years) 5.00 Volatility 115 % Risk-free rate 0.5 % Dividend yield 0.0 %
Schedule of Options issued for services	Weighted Average Weighted Remaining Average Contractual Options Exercise Price Life (years) Intrinsic Value Outstanding at December 1, 2019 1,200,000 $ 1.35 3.4 $ 721,000 Issued 950,000 1.46 4.9 — Outstanding at August 31, 2020 2,150,000 $ 1.40 3.6 $ 161,000 Exercisable at August 31, 2020 1,290,000 $ 1.36 2.7 $ 161,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	Aug. 31, 2020USD ($)
Summary of Significant Accounting Policies
Federal depository insurance coverage	$ 250,000

Loss per share (Details)

Loss per share (Details) - shares	9 Months Ended	12 Months Ended
	Aug. 31, 2020	Nov. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	18,074,000	14,112,000
Series A convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	2,280,000
Series B convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	3,787,000
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	9,801,000	7,180,000
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	2,150,000	1,200,000
Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	56,000	5,732,000

Convertible Notes (Details)

Convertible Notes (Details) - USD ($)	Aug. 31, 2020	Aug. 25, 2020	Nov. 30, 2019
Notes and Loans Payable, Current [Abstract]
Carrying value	$ 0		$ 3,243,292
Total carrying value of convertible notes payable, current			3,243,000
Notes and Loans, Noncurrent [Abstract]
Principal value	6,015,000
Debt Instrument, Unamortized Discount		$ 10,000
2018 Debentures
Notes and Loans Payable, Current [Abstract]
Principal value			2,730,000
Fair value of bifurcated contingent put option			74,000
Debt discount			(61,000)
Carrying value			2,743,000
Notes and Loans, Noncurrent [Abstract]
Principal value	3,051,000
2019 August Debenture
Notes and Loans Payable, Current [Abstract]
Principal value			550,000
Debt discount			(50,000)
Carrying value			500,000
Notes and Loans, Noncurrent [Abstract]
Principal value	100,000
Debt discount	(10,000)
Carrying value	$ 90,000
2019 October Debenture
Notes and Loans, Noncurrent [Abstract]
Principal value			500,000
Fair value of bifurcated contingent put option			29,000
Debt discount			(82,000)
Carrying value			$ 447,000

Convertible Notes - Fair Value

Convertible Notes - Fair Value Measurement Inputs (Details)	Aug. 31, 2020$ / shares	Jan. 15, 2020$ / shares	Dec. 06, 2019$ / shares
Strike price
Convertible Notes
Input		3	3
Strike price | Minimum
Convertible Notes
Input	1
Strike price | Maximum
Convertible Notes
Input	3
Terms (years)
Convertible Notes
Input	0.8	1.4	1.5
Volatility
Convertible Notes
Input	126	97	98
Risk-free rate
Convertible Notes
Input	0.2	1.7	1.6
Dividend yield
Convertible Notes
Input	0	0	0

Convertible Notes - Summary of

Convertible Notes - Summary of debt conversion (Details)	9 Months Ended
	Aug. 31, 2020USD ($)shares
Total	$ 6,015,000
Issuance of preferred stock to convert notes debt along with interest (in shares) | shares	0
Loss on debt extinguishment	$ (31,000)
2018 Debentures
Principal value	2,730,000
Remaining debt discount	(28,000)
Accrued interest	223,000
Fair value of bifurcated contingent put option	126,000
Total	3,051,000
2019 Debenture
Principal value	1,950,000
Remaining debt discount	(220,000)
Accrued interest	58,000
Fair value of bifurcated contingent put option	157,000
Total	1,945,000
2020 Debenture
Principal value	1,000,000
Remaining debt discount	(140,000)
Accrued interest	22,000
Fair value of bifurcated contingent put option	137,000
Total	1,019,000
Series A convertible preferred stock
Fair value of convertible shares	$ 1,280,000
Issuance of preferred stock to convert notes debt along with interest (in shares) | shares	127,998
Series B convertible preferred stock
Fair value of convertible shares	$ 2,031,000
Issuance of preferred stock to convert notes debt along with interest (in shares) | shares	2,031,340
Common Stock
Fair value of convertible shares	$ 2,735,000
Issuance of preferred stock to convert notes debt along with interest (in shares) | shares	2,811,198

Convertible Notes - Interest ex

Convertible Notes - Interest expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2020	Aug. 31, 2019	Aug. 31, 2020	Aug. 31, 2019
Convertible Notes.
Interest expense based on the coupon interest rate of the outstanding debt	$ 6,000	$ 55,000	$ 156,000	$ 166,000
Accretion of debt discount	3,000	390,000	136,000	907,000
Total interest expense	$ 9,000	$ 477,000	$ 292,000	$ 1,137,000
Costs incurred to defer monthly contingent payments of convertible notes	-	32,000	-	64,000

Convertible Notes - Additional

Convertible Notes - Additional Information (Details)	Aug. 25, 2020USD ($)	Aug. 31, 2020USD ($)$ / shares	Aug. 31, 2019USD ($)	Aug. 31, 2020USD ($)D$ / sharesshares	Aug. 31, 2019USD ($)
Debt Instruments [Line Items]
Conversion of note				$ 2,735,300	$ 293,726
Embedded conversion option has a fair value				(19,163)	(396,000)
Loss on induced conversion of debt		$ 0	$ 197,078	$ 0	197,078
Number of notes outstanding with embedded conversion features | shares				0
Shares payable related to debt modification	$ 10,000			$ 10,000	$ 0
Debt discount	$ 10,000
Debentures
Debt Instruments [Line Items]
Issue Of Debentures, Amount		$ 2,000,000		$ 2,000,000
Conversion price | $ / shares		$ 2		$ 2
Debt Instrument, Interest Rate, Stated Percentage		5.50%		5.50%
Commitment fee (as percent)				2.50%
Debt discount				$ 300,000
Embedded conversion option has a fair value				$ 300,000
Percent of average of the four lowest daily VWAPs during the 10 consecutive trading days				93.00%
Redemption premium (as percent)				20.00%
Loss on extinguishment of debt				$ 35,000
Percent of monthly payment of deferral fee				10.00%
Percentage of average of the four lowest daily VWAPs on basis of which conversion price is reduced				93.00%
Number of lowest daily VWAPs during the 10 consecutive trading days on basis of which conversion price is reduced				4
Number of consecutive trading days on basis of which conversion price is reduced | D				10
Debentures | Maximum
Debt Instruments [Line Items]
Conversion price | $ / shares		$ 3		$ 3
Debentures | Minimum
Debt Instruments [Line Items]
Conversion price | $ / shares		$ 2		$ 2
2018 Debentures
Debt Instruments [Line Items]
Issue Of Debentures, Amount		$ 2,730,000		$ 2,730,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2020	Aug. 31, 2019	Aug. 31, 2020	Aug. 31, 2019
Related Party Transactions
Consulting and legal expenses	$ 105,000	$ 78,000	$ 315,000	$ 270,000

Stockholders' Equity Deficit (D

Stockholders' Equity Deficit (Details) - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2020	Aug. 31, 2019	Aug. 31, 2020	Aug. 31, 2019	Apr. 03, 2020	Nov. 30, 2019
Share based compensation for services, Amount	$ 271,430	$ 341,127	$ 4,982,446	$ 1,349,608
Number of preferred shares authorized	100,000,000		100,000,000			100,000,000
Preferred shares dividend (as a percent)			2.00%
Annual preferred shares dividend (as a percent)			8.00%
Percentage of beneficial ownership	9.99%		9.99%
Series A convertible preferred stock
Number of preferred shares authorized					500,000
Original Issue Price Per Share	$ 10		$ 10
Liquidation Value Per Share	10.32		10.32
Liquidation value per share before accrued but unpaid dividends thereon			10
Series B convertible preferred stock
Number of preferred shares authorized					1,000,000
Original Issue Price Per Share	10		10
Liquidation Value Per Share	$ 10.31		10.31
Liquidation value per share before accrued but unpaid dividends thereon			$ 10
General and Administrative Expense
Share based compensation for services, Shares			200,000
Share based compensation for services, Amount			$ 500,000

Stockholders' Equity Deficit -

Stockholders' Equity Deficit - Conversion of Series A preferred Shares (Details) - Series A convertible preferred stock	9 Months Ended
	Aug. 31, 2020USD ($)D$ / shares
Liquidation value	$ 1
Number of consecutive trading days | D	10
VWAP of common stock	$ 5
Common shares trading value | $	$ 750,000

Stockholders' Equity Deficit _2

Stockholders' Equity Deficit - Conversion of Series B Preferred Shares (Details) - Series B convertible preferred stock	9 Months Ended
	Aug. 31, 2020Ditem$ / shares
Conversion price	$ 2.70
Percentage of beneficial ownership	9.99%
10 Consecutive trading days
Conversion price	$ 1
Percent of average of the four lowest daily VWAPs during the 10 consecutive trading days	93.00%
Number of lowest daily VWAPS during the specified consecutive trading days | item	4
Number of consecutive trading days | D	10
40 Consecutive trading days
Conversion price	$ 1
Number of consecutive trading days | D	40
Number of trading days | D	30
Conversion price decrease	$ 0.35

Stockholders' Equity Deficit _3

Stockholders' Equity Deficit - Financing Agreements (Details) - USD ($)	Apr. 06, 2020	Aug. 31, 2020	Aug. 31, 2019
Issuance of preferred stock to convert notes debt along with interest (in shares)		0
Issuance of common stock to convert notes payable and accrued interest		$ 2,735,300	$ 293,726
Preferred shares for cash		3,950,000
Preferred stock
Amount of beneficial conversion option for convertible preferred shares		500,000
Accumulated dividends payable		$ 200,000
Series A convertible preferred stock
Issuance of preferred stock to convert notes debt along with interest (in shares)		127,998
Number of shares issued for cash		100,000
Preferred shares for cash		$ 975,000
Series B convertible preferred stock
Issuance of preferred stock to convert notes debt along with interest (in shares)		2,031,340
Number of shares issued for cash		300,000
Preferred shares for cash		$ 2,975,000
Securities Purchase Agreement | Series A convertible preferred stock
Issuance of preferred stock to convert notes debt along with interest (in shares)	127,998
Issuance of common stock to convert notes payable and accrued interest	$ 1,300,000
Number of shares issued for cash	100,000
Preferred shares for cash	$ 1,000,000
Securities Purchase Agreement | Series B convertible preferred stock
Issuance of preferred stock to convert notes debt along with interest (in shares)	203,134
Issuance of common stock to convert notes payable and accrued interest	$ 2,000,000
Number of shares issued for cash	300,000
Preferred shares for cash	$ 3,000,000

Warrants and Options - Summary

Warrants and Options - Summary of warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Aug. 31, 2020	Nov. 30, 2019
Intrinsic Value
Beginning balance		$ 2,463,000
Ending balance	$ 1,668,000
Exercisable at May 31, 2020	$ 1,668,000
Warrants
Warrants
Beginning balance	7,180,000
Issued	3,065,000
Cashless exercise	(30,000)
Forfeited/expired	(414,000)
Ending balance	9,801,000	7,180,000
Exercisable at May 31, 2020	9,788,000
Weighted Average Exercise Price
Beginning balance	$ 2.22
Issued	2.13
Cashless exercise	0.86
Forfeited/expired	3.95
Ending balance	$ 2.11	$ 2.22
Exercisable at May 31, 2020	2.11
Weighted Average Remaining Contractual Life (years)
Beginning balance		3 years 2 months 12 days
Issued	4 years 3 months 18 days
Ending balance	3 years 1 month 6 days
Exercisable at May 31, 2020	3 years 1 month 6 days

Warrants and Options - Fair val

Warrants and Options - Fair value of warrants (Details) - Warrants	9 Months Ended
	Aug. 31, 2020$ / shares
Strike price	$ 2.12
Term (years)	5 years
Volatility	120.00%
Risk-free rate	1.30%
Dividend yield	0.00%

Warrants and Options - Modficat

Warrants and Options - Modfication of warrants (Details) - $ / shares	Feb. 12, 2020	Aug. 31, 2020
After Modification
Strike price	$ 2.20
Term (years)	3 years 8 months 12 days
Volatility	124.00%
Risk-free rate	0.90%
Dividend yield	0.00%
Before Modification
Strike price	$ 4.20
Term (years)	1 year 6 months
Volatility	164.00%
Risk-free rate	1.10%
Dividend yield	0.00%
Stock Options
Strike price		$ 1.46
Term (years)		5 years
Volatility		115.00%
Risk-free rate		0.50%
Dividend yield		0.00%

Warrants and Options - Summar_2

Warrants and Options - Summary of outstanding options (Details) - $ / shares	9 Months Ended	12 Months Ended
	Aug. 31, 2020	Nov. 30, 2019
Intrinsic Value
Beginning balance		$ 2,463,000
Ending balance	$ 1,668,000
Exercisable at May 31, 2020	$ 1,668,000
Stock Options
Options
Beginning balance	1,200,000
Issued	950,000
Ending balance	2,150,000	1,200,000
Exercisable at May 31, 2020	1,290,000
Weighted Average Exercise Price
Beginning balance	$ 1.35
Issued	1.46
Ending balance	$ 1.40	$ 1.35
Exercisable at May 31, 2020	1.36
Weighted Average Remaining Contractual Life (years)
Beginning balance		3 years 4 months 24 days
Issued	4 years 10 months 24 days
Ending balance	3 years 7 months 6 days
Exercisable at May 31, 2020	2 years 8 months 12 days
Intrinsic Value
Beginning balance		$ 721,000
Ending balance	$ 161,000
Exercisable at May 31, 2020	$ 161,000

Warrants and Options - Addition

Warrants and Options - Additional Information (Details) - USD ($)	May 01, 2020	Feb. 12, 2020	Aug. 31, 2020	Aug. 31, 2019	Aug. 31, 2020	Aug. 31, 2019
Share based compensation related to warrants modification, Amount					$ 255,008
Number of modified warrants	168,000	245,625
General and administrative expenses			$ 1,491,613	$ 968,383	8,659,819	$ 3,406,853
Research and development expenses			613,707	$ 786,600	896,908	2,672,715
Unrecognized stock-based compensation			$ 900,000		$ 900,000
Certain consultants and service providers
Number of warrants issued in exchange for services rendered					901,000
Certain consultants and legal service providers
Number of warrants issued in exchange for services rendered					250,000
Exercise price of warrant			$ 2.12		$ 2.12
Direct offering cost			$ 100,000		$ 100,000
Minimum | Certain consultants and service providers
Warrants exercisable term			3 years		3 years
Exercise price of warrant			$ 2		$ 2
Minimum | Certain consultants and legal service providers
Warrants exercisable term			6 months		6 months
Maximum | Certain consultants and service providers
Warrants exercisable term			5 years		5 years
Exercise price of warrant			$ 2.12		$ 2.12
Maximum | Certain consultants and legal service providers
Warrants exercisable term			5 years		5 years
After Modification
Warrants exercisable term		2 years
Exercise price of warrant	$ 2	$ 2.33
Share based compensation related to warrants modification, Amount					$ 200,000
Amount of consideration received		$ 20,000
After Modification | Minimum
Warrants exercisable term	2 years
After Modification | Maximum
Warrants exercisable term	3 years
Options and Warrants
General and administrative expenses					$ 5,000,000
Research and development expenses						$ 500,000
Officers
Number of warrants issued in exchange for services rendered					1,500,000
Exercise price of warrant			$ 2.12		$ 2.12
Officers | Minimum
Warrants exercisable term			6 months		6 months
Officers | Maximum
Warrants exercisable term			5 years		5 years

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent events	Sep. 15, 2020USD ($)shares
Subsequent Event [Line Items]
Common stock issued to settle outstanding payables (in shares) | shares	416,667
Outstanding payables	$ 750,000
Outstanding receivable	61,000
Fair value the common shares issued	$ 550,000